

Chemotherapy drug delivery from calcium phosphate nanoparticles

Xingguo Cheng
Liisa Kuhn

Oral Rehabilitation, Biomaterials and Skeletal Development, University of Connecticut Health Center, Farmington, CT, USA

Abstract: Calcium phosphate nanoparticles (nanoCaP) conjugated with *cis*-diamminedichloro-platinum (CDDP, cisplatin) were prepared through the electrostatic binding of an aquated species of cisplatin to the nanoCaP in a chloride-free solution. The agglomeration of the nanoCaP that typically occurs during synthesis of CaP was controlled through the addition of DARVAN® 811 immediately after precipitation and before drug conjugation. In vitro drug release studies were completed and showed a sustained release of CDDP from the nanoconjugates over time. The cytotoxicity of the nanoCaP/CDDP was compared to that of the free drug in an in vitro cell proliferation assay using the CDDP resistant A2780cis human ovarian cancer cell line. The CDDP released from the nanoconjugates was equally effective as the free drug against the A2780cis cell line. Direct addition cytotoxicity studies revealed that the sterically-stabilized, negatively-charged drug nanoconjugates are unable to overcome drug resistance and had an increased IC50 value as compared to the free drug.

Keywords: calcium phosphate, cisplatin, chemotherapy, nanoparticle, drug delivery

Introduction

Attachment of a pharmaceutical to a particulate drug delivery system is a tactic that has long been employed to sustain drug delivery. Particulate drug carrier systems for tumor specific targeting of anti-cancer drugs include liposomes (Gregoriadis 1995; Allen and Moase 1996; Vicent and Duncan 2006), polymer microspheres (Fung and Saltzman 1997; Liu et al 2003; Lin et al 2005; Foger et al 2006) and recently nanoparticles (Barbe et al 2004; Ambruso et al 2006; Dong and Feng 2006; Farokhzad et al 2006). Although liposomal systems have made the most headway in the clinic, they are under further optimization to be safer to normal tissues and long-circulating in blood, yet able to efficiently accumulate and transfer drug in a sustained manner to targeted sites (Hong et al 1999). For biodegradable polymer-based drug delivery systems, there are concerns that polymer acidic byproducts or degrading polymer fragments can adversely affect the drug they are delivering or the tissues they interact with. Often an undesirable late stage, uncontrolled and massive drug release is observed with polymer-based drug delivery systems (Spenlehauer et al 1989). Bioceramics, such as calcium phosphates (CaP), represent another class of materials suitable for use as a carrier for drugs, non-viral gene delivery, antigens, enzymes, and proteins. CaP can be produced at a low cost and is simple to manufacture. Hydroxyapatite (HA) is a type of calcium phosphate that has a similar chemical structure to bone mineral, and hence has excellent biocompatibility, bioactivity, and high affinity to proteins (Gorbunoff 1984a, 1984b; Spenlehauer et al 1989), DNA (Welzel et al 2004; Bisht et al 2005), chemotherapy drugs (Barroug et al 2004), and antigens (He et al 2000).

Localized pharmaceutical treatments utilizing CaP as a drug carrier have been achieved by injections (He et al 2000) or surgical placement of disks, pellets or particulates (Yamamura et al 1994; Itokazu et al 1998; Rogers-Foy et al 1999; Benghuzzi

Correspondence: Liisa Kuhn
University of Connecticut Health Center,
Farmington, CT, 06030-1615, USA
Tel +1 860 679 3922
Fax +1 860 679 4889
Email lkuhn@uchc.edu

2000; Mizushima et al 2006). The localized drug release from these CaP-based controlled release systems minimized the high concentration of drugs typically required in the bloodstream and other organs to achieve therapeutic outcomes. The CaP also provided a means to minimize unnecessary systemic toxicity and reduce the need for repeated dosing often required of most drugs. Due to the low solubility of the HA type of CaP in physiological conditions, HA remains for long periods after *in vivo* subcutaneous placement. The large sintered disks and large particle sizes of HA utilized in the previously researched formulations would remain *in vivo* long after drug release. This led to our interest in investigating nano-sized CaP particles that could speed carrier resorption, allow greater tumor or tissue perfusion, and perhaps overcome drug resistance through intracellular drug/particle uptake observed with particulate drug delivery formulations (Minko et al 1998). Particle enhanced endocytosis may endow the particulate drug delivery systems with an ability to bypass p-glycoprotein efflux pump and lead to sequestration of anticancer drugs in acidic intracellular compartments, yielding high cytotoxicity (Lee et al 2005).

In order to use nanoCaP crystals as an efficient drug carrier for localized chemotherapy treatment, it is important that the chemotherapy drug can be loaded and released in a controlled manner. Moreover, it is also important that the drug released is chemically active and effective over a long period of time. Therefore we investigated these variables using Cisplatin (CDDP), a commonly used chemotherapy drug with high antitumor activity (Long and Repta 1981; Barroug et al 2004) as the model drug. Our approach can be generalized to other drugs and biomolecules due to the versatility of the CaP crystal surface to bind both positively and negatively charged molecules through simple adsorption. In the present study, we describe the preparation of nanoCaP/CDDP conjugates with controlled size and purity. The *in vitro* drug release profile of the nanoconjugates is investigated. The cytotoxicity of the released drug and directly added nanoCaP/CDDP is compared to that of the free drug in an *in vitro* cell proliferation assay using the CDDP resistant A2780cis human ovarian cancer cell line.

Experimental procedures

Nano-calcium phosphate particle synthesis

NanoCaP was synthesized by co-precipitation from the addition of equal volumes of a 30 mM $\text{Ca}(\text{NO}_3)_2$ solution and a 30 mM K_2HPO_4 solution which are both filtered through 0.1 μm filtration device (Millipore, Boston, USA)

separately, followed by immediate addition of 1.67(v/v)% of 0.2 μm filtered DARVAN[®]811 (sodium polymethacrylate, $M_w = 3,300$, R.T. Vanderbilt Company, Inc. Norwalk, CT, USA) as a dispersing agent. All reagents are ACS grade and purchased from Sigma Chemical Co., (St. Louis, MO), unless noted otherwise. After 1 hr stirring, a pellet of nanoCaP was collected by centrifugation at 12,000 rpm (20,076 g) for 30 min. Before binding, the nanoCaP pellet was redispersed in ultrapure H_2O as a wash step, and then collected by centrifugation at 12,000 rpm for 30 min.

NanoCaP/CDDP conjugate synthesis

CDDP (Sigma Chemical Co., St. Louis, MO) was bound to nanoCaP by following a slight modification of the electrostatic conjugate preparation procedure we developed previously (Barroug and Glimcher 2002). Following the recommendation of Dr. S. Lippard, (Chemistry Dept., Massachusetts Institute of Technology, Cambridge, MA, USA), the aquated form of CDDP was prepared and used instead of CDDP to more efficiently form the conjugates. Aquated CDDP was prepared by reacting 90 mM AgNO_3 solution with CDDP solution (about 1000 $\mu\text{g}/\text{mL}$) at a 2:1 molar ratio. The reaction mixture was placed on a thermal rocker (Lab-Line[®], model 4637) for 12–24 hrs and kept protected from light. The silver chloride precipitate was removed by several centrifugation steps at 3000 rpm (1000 g) for 20 min. The remaining supernatant was filtered through a 0.2 μm filter. The final concentration of aquated CDDP was determined by Pt analysis using an Atomic Absorption Spectrophotometer (AAS) (Model 5100, Perkin Elmer, Shelton, CT, USA).

The nanoconjugates were formed by adding 0.625 mL of 20 mM potassium phosphate buffer (KPB, pH = 6) to 31.55 mg of a wet nanoCaP pellet (which corresponds to 5 mg of dry CaP as determined by oven drying), and sonicating for 10 sec. Aquated CDDP (0.625 mL with initial binding CDDP concentration C_0) was added, and the sample was put in a thermorocker at 37 °C, speed 5 (LAB-LINE[®] thermorocker, Model 4637, Barnstead Thermolyne, IL, USA) for 4 hrs. The conjugates thus formed were centrifuged at 12,000 rpm (20,076 g) for 30 min. The supernatant, which contained unbound CDDP, was decanted and measured for final binding supernatant CDDP concentration (C_f) by AAS. The pellet was washed with 0.25 mL 10 mM KPB buffer and centrifuged at 12,000 rpm (20,076 g), 30 min. The supernatant from this KPB wash was decanted and measured by AAS to determine KPB wash supernatant CDDP concentration (C_{KPB}). This pellet was rinsed with 0.21 mL of 0.9% NaCl solution for 30 min. on the thermorocker (37 °C, speed 5)

after brief sonication. The sample was centrifuged again at 12,000 rpm for 30 min. to collect the nanoCaP/CDDP conjugates. The supernatant was decanted and measured for saline wash supernatant CDDP concentration (C_w). The drug loading was calculated by the following equation:

$$\begin{aligned} & \mu\text{g adsorbed CDDP/mg of CaP} \\ & = (C_0 * V_0 - C_f * V_f - C_{KPB} * V_{KPB} - C_w * V_w) / \text{mg CaP} \end{aligned} \quad (1)$$

where V_0 , V_{KPB} , and V_w are the volume of initial aquated CDDP, 10 mM KPB buffer, and NaCl used, respectively. Drug loading efficiency defined as $\mu\text{g adsorbed CDDP}/\mu\text{g CDDP}$ in the starting solution was also calculated.

Three batches of nanoconjugates were synthesized aseptically for the different studies. Volumes of the precipitation solutions were varied proportionally depending on the yield of conjugates required. The drug loading of the nanoconjugates was controlled by changing the initial aquated CDDP concentration (C_0). The drug loading of the nanoconjugates used for the direct addition cytotoxicity study was 112 $\mu\text{g}/\text{mg}$ obtained by using 1052 $\mu\text{g}/\text{mL}$ aquated CDDP. The drug loading efficiency was 0.85. The drug loading of nanoconjugates used for in-vitro drug release study was 88 $\mu\text{g}/\text{mg}$ by using 900 $\mu\text{g}/\text{mL}$ aquated CDDP and the drug loading efficiency was 0.78. The drug loading of the conjugates used for cytotoxicity test was 35 $\mu\text{g}/\text{mg}$ by using 552 $\mu\text{g}/\text{mL}$ aquated CDDP and drug loading efficiency was 0.5.

Physical and chemical characterization of nanoCaP and nanoCaP/CDDP conjugates

Samples were prepared for transmission electron microscopy (TEM) by dispersing nanoCaP/CDDP conjugates in ultrapure H_2O at about 1 mg/mL concentration with an Ultrasonic 1000L Cell Disruptor (Ultrasonic Power Corporation, IL, USA) for 1 minute. One drop of this liquid was immediately transferred by a micropipette to a 3 mm diameter Formvar coated copper TEM grid and slowly evaporated to dryness. The samples on the TEM grid were analyzed using a 100cx JEOL TEM at 80 kV in brightfield (BF) modes.

The chemical structure of nanoCaP was determined by FTIR as follows. Infrared absorption spectra were obtained from nanoCaP in a KBr pellet using a Bruker Tensor 27 Fourier transform infrared (FTIR) spectrometer with a resolution of 0.1cm^{-1} . X-ray diffraction analysis was used to determine the crystal structure of nanoCaP. The samples were scanned with Cu-K α x-ray radiation from a Philips XRD 2500 at 40 KV and 20 mA, using a step size of 0.02° and a step time

of 1.2 s over a 2θ range of 10–70. The particle size of the nanoCaP and nanoCaP/CDDP conjugates were measured on samples dispersed in ultrapure H_2O at about 1 mg/mL concentration by Ultrasonic 1000L Cell Disruptor. The particle size and Z-potential of nanoparticles was measured on 90 Plus particle sizer coupled with Z-potential analyzer (Brookhaven Instruments, NY, USA).

In vitro drug release studies

Release studies were conducted by dispersing 40 mg of nanoCaP/CDDP conjugates (88 $\mu\text{g}/\text{mg}$ loading), by mixing and brief vortexing, in 0.8 mL PBS and rocking at 37 °C, 20 cycle/min. Supernatants were collected at 1hr, 6 hr, 1, 3, 7, 12, and 16 days, after centrifugation at 9,000 rpm (7,000 g) for 10 minutes. The released drug in the unfiltered supernatant was measured by AAS. Full replacements of release media were made at each time point.

In vitro cytotoxicity testing

For in vitro cytotoxicity activity studies, the CDDP-resistant cell line was used: A2780cis human ovarian carcinoma cell line (Sigma, 93112517) and cultured according to supplier's descriptions. Briefly, cells were cultured in RPMI1640 medium, supplemented with 2 mM Glutamine and 10% Fetal Bovine Serum (FBS) in a humid atmosphere at 37 °C and 5% CO_2 . Cells were supplemented with 1 μm CDDP to the culture media every 2–3 passages, post-attachment. The CellTiter96® AQueous One (Promega Corporation, Madison, WI, USA) colorimetric proliferation assay was used to determine the IC50 value (50% inhibitory concentration) evaluated from 12 two-fold dilutions of CDDP in 0.9% saline (free drug), nanoconjugates, nanoCaP and free drug, or CDDP released from the nanoconjugates. The highest concentrations of test samples were prepared in the drug master plate prior to dilution as follows: CDDP was dissolved in 0.9% saline at 1000 $\mu\text{g}/\text{mL}$ and diluted in PBS to prepare a free drug solution of 200 μg CDDP/mL. CDDP released from the nanoconjugates was obtained from the supernatant of 40 mg of nanoconjugates (loaded at 35 μg CDDP/mg nanoCaP) incubated in 0.8 mL PBS for 3d on a rocker at 37 °C, 20 cycles/min. Three days were necessary to achieve a CDDP concentration high enough to obtain an IC50 value. Five milligrams of nanoCaP/CDDP, synthesized aseptically with a drug loading of 112 μg CDDP/mg CaP, was dispersed in 0.8 mL PBS (CDDP 700 $\mu\text{g}/\text{mL}$ if totally released) for the highest nanoconjugate concentration directly added. To confirm that the particulate nanoconjugates were diluted evenly across the wells,

measurements of the total Pt concentration in all the wells of the drug master plate were made by AAS after dissolving the nanoconjugate solutions in dilute HCl. Five milligrams of nanoCaP was dispersed in 0.8 mL free drug solution for the nanoCaP not conjugated to free drug sample, directly added to cells.

Preliminary investigations of the growth rate of A2780cis were conducted to determine the proper cell seeding number that would remain in the linear range of the assay throughout the study. The cytotoxicity assay was conducted as follows: twenty-four hours after seeding 2000 A2780cis cells in 50 μ l of media on 96 well plates, 50 μ l PBS, or PBS with drug, carrier or nanoconjugates was added to the wells. Five replicates were tested for each sample. Following two days of continuous exposure, 20 μ l of CellTiter96[®] Aqueous One (Promega) colorimetric proliferation reagent was added to each well, and then the plates were incubated for 4 more hours before being read on a Spectramax Plus384 spectrophotometer (Molecular Biosciences, Sunnyvale, CA, USA) at an absorbance value of 490nm. Absorbance values were converted to IC50 values using the four parameter logistic equation:

$$Y = (A_{\max} - A_{\min}) / (1 + (x/IC50)^n) + A_{\min} \quad (2)$$

where

Y = observed absorbance

A_{\max} = absorbance of control cells

A_{\min} = absorbance of cells in presence of highest agent concentration

x = drug concentration (μ g/ml)

n = slope of curve

Samples were analyzed for statistically significant differences using the Student's T-test ($p < 0.05$).

Results

Physical and chemical characterization of the nanoCaP and the nanoCaP/CDDP conjugates

A combination of several methods was used to fully characterize the nanoconjugate shape, size, chemistry and structure. TEM images showed that the nanoconjugates are spherical and well dispersed (Figure 1a). The mean particle size of the nanoCaP precipitated with DARVAN 811 before conjugation with CDDP was 129 ± 33 nm (50% below 125.4 nm, 90% below 181.3 nm), and the zeta-potential = -45.59 mV. The size and zeta-potential slightly decreased after adsorbance of CDDP: 106.5 ± 35.4 nm (50% below 101.1 nm, 90% below 163.3 nm), zeta-potential = -27.9 mV (Figure 1b). Solutions of nanoconjugates remain stably dispersed for periods of up to at least two weeks. The FTIR spectra of the nanoCaP and the nanoconjugates have similarities to HA (Elliott 1994; Zhang and Colwell 2004; Liu et al 2005), and not other calcium phosphate phases, except that several peaks associated with the DARVAN 811 are present in the nanoparticles (Figure 2). However, there is a lack of resolution of the P-O absorption bands, indicating that the sample may contain amorphous calcium phosphate (Legeros et al 2005). The R-COO- stretch in the DARVAN 811 is changed from 1573 cm^{-1} to 1559 cm^{-1} which is possibly due to intermolecular bridge R-COO-Ca complex formation with the CaP (Zhang et al 2006). The X-ray diffraction spectra (Figure 3) of the nanoCaP contains broad peaks characteristic of HA. The broad peaks of the nanoCaP relative to the HA standard peaks indicates that the crystals are nanometer in size, poorly crystalline or perhaps amorphous. The sample does not show any evidence of contamination from other crystalline calcium phosphate phases.




Figure 1 (a) TEM image of nanoCaP/CDDP conjugates. (b) Particle size analysis of nanoCaP/CDDP conjugates redispersed in H_2O at 1 mg/mL concentration. NanoCaP/CDDP particle size = 106.5 ± 35.4 nm (mean size \pm standard error, 50% below 101.1 nm, 90% below 163.3 nm), Z-potential = -27.9 mV. The control NanoCaP: Particle size = 129 ± 33 nm, 50% below 125.4 nm, 90% below 181.3 nm. Z-potential = -45.59 mV.




Figure 2 FTIR spectrum of (a) DARVAN 811 (b) Commercial hydroxyapatite standard and (c) NanoCaP formed in the presence of DARVAN 811 (d) NanoCaP/CDDP conjugates.

In vitro drug release from nanoCaP/CDDP conjugates

The amount of CDDP released from the nanoconjugates into PBS, pH = 7.4 during gentle rocking at 37 °C at various time points is shown in Figure 4a. The results are also expressed as a percentage of the total amount bound (Figure 4b). There is a burst release of drug in the first day, followed by a slower, but continuous, release of drug over the time tested. After 16-days in PBS with eight solution changes, 30% of the bound drug released.

Cytotoxicity of nanoCaP/CDDP conjugates

The effect of the CDDP conjugated to nanoCaP on the proliferation of A2780cis cancer cells was evaluated indirectly and directly by (a) addition of the CDDP released from the nanoconjugates during incubation in PBS for three days, and (b) direct addition of the nanoconjugates to the cells in culture. The IC₅₀ value obtained for the nanoconjugate-released CDDP was not significantly different from the free drug ($p > 0.05$) (Figure 5), indicating the conjugation procedure and the release process do not adversely affect CDDP. The IC₅₀ value obtained after direct addition of the nanoconjugates is also shown in Figure 5. Determination of the IC₅₀ value for directly added nanoconjugates was complicated by the fact that the nanoCaP and the nanoconjugates themselves have an absorbance maximum at 490 nm, the same as the formazan product produced by the viable cells in the assay. Therefore, it was necessary to deduct the interference of the nanoCaP using the readings from wells prepared using the

same conditions as above (same seeding cell number, same nanoconjugate or nanoCaP concentration and volume, same culture time) without the addition of CellTiter96® reagent, as shown in Figure 6. The IC₅₀ values obtained this way indicate that the addition of the carrier alone (nanoCaP) to a free drug solution slightly, but significantly, increases the IC₅₀ value relative to the free drug alone. This provides indirect evidence that the nanoCaP itself is not cytotoxic at the concentration tested. The IC₅₀ value of the nanoconjugates was found to be significantly higher than the free drug (17.6 ± 2.7 vs 3.2 ± 0.2) indicating that a portion of the CDDP attached to the nanoconjugates is protected from direct interaction with the cells during the two-day test period.

Discussion

In our previous experiments with CDDP release from different types CaP, we observed that the less crystalline the CaP, the slower the release of drug (Barroug et al 2004). This effect was correlated to particle surface area: particles with higher surface areas bind more drug and release it more slowly and less completely than particles with lower surface areas. Therefore, varying the crystallinity is one means of controlling drug release in inorganic particle-based drug delivery systems. Given that the nanoCaP of this study appears to be even less crystalline than the CaP tested in our previous work, it is not surprising that the initial burst release and the cumulative drug release from the nanoconjugates in the present study was even lower than that observed previously for CaP. The reduction of a burst release and enhanced sustained release possible with the nanoconjugates is desirable for in vivo applications. While there is low cumulative release in neutral PBS, the nanoconjugates are completely soluble in acidic solutions. This property may make the nanoCaP/CDDP drug




Figure 3 XRD spectrum of nanoCaP particles compared to a hydroxyapatite standard (JCPDS, #09-0432).




Figure 4 Drug release profile of nanoCaP/CDDP conjugates (88 ug/mg loading). (a) Amount of CDDP released over time in PBS, pH = 7.4 (b) Cumulative release over time of CDDP in PBS, pH = 7.4.

delivery system particularly suited for in vivo intratumoral drug delivery applications in which the acidic pH of tumor tissue will lead eventually to complete drug release.

The reduced cytotoxicity of the nanoconjugates relative to free drug seen in the direct addition studies also confirms that a large portion of CDDP attached to the CaP is not released over two days in neutral pH cell culture medium. From the in vitro release studies (Figure 4), approximately 12% of the total CDDP bound would be expected to be released by the end of the two day incubation with cells. The 12% is probably an overestimate since the release study was conducted with solution agitation and multiple total solution replacements, while the cell culture media was not disturbed or replaced. Assuming 10% release, of the 350 $\mu\text{g}/\text{ml}$ available for release from the conjugates, only 35 $\mu\text{g}/\text{ml}$ of free drug would have been available at the highest concentration to the cells compared to the 100 $\mu\text{g}/\text{ml}$ in the free drug wells. If the concentrations of the nanoconjugates were adjusted to this theoretical value and the IC_{50} values recalculated, the IC_{50} would be 1.7 $\mu\text{g}/\text{mL}$, which is less than free drug (3.2 $\mu\text{g}/\text{mL}$). Therefore it appears that more of the CDDP than expected from cell-free in vitro release studies is being released when in contact with cells. This would be possible if some endocytosis of the nanoconjugates occurred as has been reported for particle based drug delivery systems (Minko et al 1998).

Previous studies with CaP have shown that unsintered microcrystals of HA are readily taken up by cancer cells (Aoki 1994), therefore we had anticipated extensive particle-assisted drug transport. If this had been the case, then the nanoconjugates would have overcome the drug resistance of the A2780cis cells (lower IC_{50} than free drug), which

they did not. There is literature indicating that negatively charged particles are less likely than neutral particles to be taken up by cells (Bonhomme et al 1992), and since the nanoCaP/CDDP is negatively charged, cellular uptake may have been reduced because of the negative surface charge. Endocytotic uptake can be categorized into nonspecific fluid phase endocytosis, adsorptive endocytosis and specific receptor-mediated endocytosis (Yi et al 2005). Adsorptive endocytosis requires nanoparticle adsorption on the cell membrane to obtain cytotoxicity and has been observed for doxorubicin-loaded polyalkylcyanoacrylate nanoparticles (Vauthier et al 2003). CaP crystals with unmodified surfaces have been shown to adsorb to cells in culture (Mandel and Riese 1991), therefore particle uptake of our nanoCaP was expected. However, in the present study we modified the surface of the nanoCaP with DARVAN 811 to prevent the adhesion of nanoparticles to each other through steric stabilization. This modification appears to have also prevented or greatly reduced cell membrane adhesion required for CaP particle-assisted drug transport. Overcoming this may require applying an additional surface modification such as a tumor cell targeting ligand (eg, folic acid, VEGF) (Marcucci and Lefoulon 2004; Minko et al 2004).

Conclusion

Stably dispersed nanoparticles of CaP were synthesized by the addition of DARVAN 811 immediately after precipitation. Aqueated CDDP was simply and efficiently adsorbed




Figure 5 Comparison of IC_{50} values obtained for the cytotoxicity testing of CDDP released after incubation of the nanoconjugates in PBS: (a) Free drug control, (b) CDDP released from the nanoCaP/CDDP conjugates. (c)–(e) are from the direct addition study: (c) Free drug control, (d) NanoCaP + Free drug, (e) NanoCaP/CDDP conjugates particles directly added to the cells. (*) denotes significant difference ($p < 0.05$, Student's T-test) from free drug control.




Figure 6 Demonstration of IC50 value determination of nanoCaP/CDDP conjugates on A2780Cis cancer cell lines. NanoCaP and nanoCaP/CDDP conjugate particles have interference around 490 nm at higher concentrations (see interference plot above). This interference was determined at the same test conditions but without adding Celltiter96 solution. It is subtracted from the raw data to give treated data (treated = raw – interference). The 4-parameter sigmoidal fit of this treated data is used to calculate the IC50 value.

to the surface of CaP nanoparticles through electrostatic interactions. The high surface area of the CaP nanoparticles led to a reduction of the CDDP burst release and greater sustained release relative to more crystalline, micron-sized agglomerated particles of CaP previously tested. In vitro cytotoxicity testing showed that the CDDP released from the nanoconjugates retained complete activity during conjugation and release and had comparable cytotoxicity to free drug. The nanoCaP alone was not cytotoxic. CDDP release from CaP nanoconjugates in neutral pH was slow and complete release was limited (30%), therefore the direct addition studies showed reduced cytotoxicity of the nanoconjugated CDDP relative to free drug. Particle assisted drug transport was not a highly active mechanism in this formulation, possibly due to the negative surface charge or steric stabilization by the DARVAN 811. However, we postulate that in acidic environments such as tumor tissues, the CaP nanoconjugates can slowly dissolve and completely release the adsorbed drug. The favorable properties of nanoCaP/CDDP conjugates warrant their further investigation in intratumoral anti-cancer drug delivery applications.

Acknowledgments

The authors gratefully acknowledge financial support from The Susan G. Komen Breast Cancer Foundation (Basic, Clinical and Translational Breast Cancer Research Grant BCTR0504344).

References

Allen TM, Moase EH. 1996. Therapeutic opportunities for targeted liposomal drug delivery. *Advanced Drug Delivery Reviews*, 21:117–33.

- Ambruosi A, Khalansky AS, Yamamoto H, et al. 2006. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. *Journal Of Drug Targeting*, 14:97–105.
- Aoki H. 1994. Medical applications of hydroxyapatite. Tokyo: Takayama Press System Center Co., Inc. p 106–9.
- Barbe C, Bartlett J, Kong LG, et al. 2004. Silica particles: a novel drug-delivery system. *Advanced Materials*, 16:1959–66.
- Barroug A, Glimcher MJ. 2002. Hydroxyapatite crystals as a local delivery system for cisplatin: adsorption and release of cisplatin in vitro. *Journal of Orthopaedic Research*, 20:274–80.
- Barroug A, Kuhn LT, Gerstenfeld LC, et al. 2004. Interactions of cisplatin with calcium phosphate nanoparticles: in vitro controlled adsorption and release. *Journal of Orthopaedic Research*, 22:703–8.
- Benghuzzi H. 2000. Long-term sustained delivery of 3'-azido-2',3'-dideoxythymidine in vivo by means of HA and TCP delivery devices. *Biomedical Sciences Instrumentation*, 36:343–8.
- Bisht S, Bhakta G, Mitra S, et al. 2005. pDNA loaded calcium phosphate nanoparticles: highly efficient non-viral vector for gene delivery. *International Journal of Pharmaceutics*, 288:157–68.
- Bonhomme L, Mathieu MC, Amdidouche D, et al. 1992. Intratumor treatment of C3H mouse mammary carcinoma with 5-fluorouracil adsorbed on activated charcoal particles. *Anti-Cancer Drugs*, 3:261–6.
- Dong Y, Feng S-S. 2006. Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel. *Journal Of Biomedical Materials Research. Part A*, 78:12–19.
- Elliott J. 1994. Structure and chemistry of the apatites and other calcium orthophosphates. Elsevier. 389 p.
- Farokhzad OC, Karp JM, Langer R. 2006. Nanoparticle-aptamer bioconjugates for cancer targeting. *Expert Opinion On Drug Delivery*, 3:311–24.
- Foger F, Noonpakdee W, Loretz B, et al. 2006. Inhibition of malarial topoisomerase II in Plasmodium falciparum by antisense nanoparticles. *International Journal of Pharmaceutics*, 319:139–46.
- Fung LK, Saltzman WM. 1997. Polymeric implants for cancer chemotherapy. *Advanced Drug Delivery Reviews*, 26:209–30.
- Gorbunoff MJ. 1984a. The interaction of proteins with hydroxyapatite : I. Role of protein charge and structure. *Analytical Biochemistry*, 136:425–32.
- Gorbunoff MJ. 1984b. The interaction of proteins with hydroxyapatite : II. Role of acidic and basic groups. *Analytical Biochemistry*, 136:433–9.
- Gregoriadis G. 1995. Engineering liposomes for drug delivery: progress and problems. *Trends in Biotechnology*, 13:527–37.
- He Q, Mitchell AR, Johnson SL, et al. 2000. Calcium phosphate nanoparticle adjuvant. *Clinical and Diagnostic Laboratory Immunology*, 7:899–903.
- Hong RL, Huang CJ, Tseng YL, et al. 1999. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial? *Clinical Cancer Research*, 5:3645–52.
- Itokazu M, Sugiyama T, Ohno T, et al. 1998. Development of porous apatite ceramic for local delivery of chemotherapeutic agents. *Journal of Biomedical Materials Research*, 39:536–8.
- Lee ES, Na K, Bae YH. 2005. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. *Journal of Controlled Release*, 103:405–18.
- Legeros RZ, Mijares D, LeGeros JP, et al. 2005. Amorphous calcium phosphate (ACP): formation and stability. *Key Engineering Materials*, 284–6:7–10.
- Lin R, Shi Ng L, Wang C-H. 2005. In vitro study of anticancer drug doxorubicin in PLGA-based microparticles. *Biomaterials*, 26:4476–85.
- Liu TY, Chen SY, Liu DM, et al. 2005. On the study of BSA-loaded calcium-deficient hydroxyapatite nano-carriers for controlled drug delivery. *Journal of Controlled Release*, 107:112–21.
- Liu Z, Ballinger JR, Rauth AM, et al. 2003. Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres. *The Journal of Pharmacy and Pharmacology*, 55:1063–73.

- Long D, Repta A. 1981. Cisplatin: chemistry, distribution and biotransformation. *Bipharm Drug Disposition*, 2:1–16.
- Mandel N, Riese R. 1991. Crystal-cell interactions: crystal binding to rat renal papillary tip collecting duct cells in culture. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, 17:402–6.
- Marcucci F, Lefoulon F. 2004. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. *Drug Discovery Today*, 9:219–28.
- Minko T, Dharap SS, Pakunlu RI, et al. 2004. Molecular targeting of drug delivery systems to cancer. *Current Drug Targets*, 5:389–406.
- Minko T, Kopeckova P, Pozharov V, et al. 1998. HEMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. *Journal of Controlled Release: Official Journal of the Controlled Release Society*, 54:223–33.
- Mizushima Y, Ikoma T, Tanaka J, et al. 2006. Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs. *Journal of Controlled Release: Official Journal of the Controlled Release Society*, 110:260–5.
- Rogers-Foy JM, Powers DL, Brosnan DA, et al. 1999. Hydroxyapatite composites designed for antibiotic drug delivery and bone reconstruction: a caprine model. *Journal of Investigative Surgery*, 12:263–75.
- Spentehauer G, Vert M, Benoit JP, et al. 1989. In vitro and In vivo degradation of poly(D,L lactide/glycolide) type microspheres made by solvent evaporation method. *Biomaterials*, 10:557–63.
- Vauthier C, Dubernet C, Chauvierre C, et al. 2003. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. *Journal of Controlled Release*, 93:151–60.
- Vicent MJ, Duncan R. 2006. Polymer conjugates: nanosized medicines for treating cancer. *Trends in Biotechnology*, 24:39–47.
- Welzel T, Radtke I, Meyer-Zaika W, et al. 2004. Transfection of cells with custom-made calcium phosphate nanoparticles coated with DNA. *Journal of Materials Chemistry*, 14:2213–17.
- Yamamura K, Iwata H, Osada T, et al. 1994. Anticancer effects of adriamycin-loaded hydroxyapatite implants determined in a swarm rat chondrosarcoma model. *Japanese Journal of Pharmacology*, 65:289–91.
- Yi YW, Kim JH, Kang HW, et al. 2005. A polymeric nanoparticle consisting of mPEG-PLA-Toco and PLMA-COONa as a drug carrier: improvements in cellular uptake and biodistribution. *Pharmaceutical Research*, 22:200–8.
- Zhang JX, Xu Q, Tanaka H, et al. 2006. Improvement of the dispersion of Al₂O₃ slurries using EDTA-4Na. *Journal of the American Ceramic Society*, 89:1440–2.
- Zhang K, Colwell JC. 2004. *Bioceramics*, New Orleans: Trans Tech Publications.